Compare PAI & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PAI | NYXH |
|---|---|---|
| Founded | 1973 | 2009 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 114.7M | 137.5M |
| IPO Year | N/A | 2021 |
| Metric | PAI | NYXH |
|---|---|---|
| Price | $11.50 | $0.85 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $4.20 |
| AVG Volume (30 Days) | 21.9K | ★ 217.2K |
| Earning Date | 01-01-0001 | 11-05-2026 |
| Dividend Yield | ★ 4.78% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $275.91 |
| Revenue Next Year | N/A | $93.27 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.24 | $0.80 |
| 52 Week High | $12.95 | $5.92 |
| Indicator | PAI | NYXH |
|---|---|---|
| Relative Strength Index (RSI) | 48.01 | 23.47 |
| Support Level | $11.24 | N/A |
| Resistance Level | $12.35 | $1.69 |
| Average True Range (ATR) | 0.08 | 0.05 |
| MACD | 0.03 | -0.05 |
| Stochastic Oscillator | 76.92 | 5.85 |
Western Asset Investment Grade Income Fund Inc is a closed-end diversified investment company. Its primary investment objective is to seek a high level of current income, consistent with prudent investment risk, through investment in a diversified portfolio of debt securities. To a lesser extent, the fund also invests in privately placed debt securities and in certain equity securities. Capital appreciation is its secondary investment objective. The fund invests a majority of its net assets in fixed income securities that are rated in the Baa or BBB categories or above at the time of purchase by one or more Nationally Recognized Statistical Rating Organizations (NRSROs) or unrated securities of comparable quality at the time of purchase (as determined by the investment adviser).
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.